- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Target Mutant KRAS with Molecular Glue ; volume:19 ; number:11 ; year:2023 ; pages:1147
Synfacts ; 19, Heft 11 (2023), 1147
- DOI
-
10.1055/s-0042-1752293
- URN
-
urn:nbn:de:101:1-2023113011564667453322
- Rechteinformation
-
Kein Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:26 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Ähnliche Objekte (12)
Beyond KRAS: Practical Molecular Targets in Pancreatic Adenocarcinoma
Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
Identification and functional characterization of novel cancer targets in mutant KRAS-driven malignancies
A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
A pan-KRAS degrader for the treatment of KRAS-mutant cancers
Current therapy of KRAS-mutant lung cancer
Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer
Synergistic effects of FGFR1 and PLK1 inhibitors target a metabolic liability in KRAS ‐mutant cancer
Restoration of mutant K-Ras repressed miR-199b inhibits K-Ras mutant non-small cell lung cancer progression
Targeting mutant KRAS in pancreatic cancer: futile or promising?
The cholesterol uptake regulator PCSK9 promotes and is a therapeutic target in APC/KRAS-mutant colorectal cancer
Beyond KRAS: Practical Molecular Targets in Pancreatic Adenocarcinoma
Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
Identification and functional characterization of novel cancer targets in mutant KRAS-driven malignancies
A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
A pan-KRAS degrader for the treatment of KRAS-mutant cancers
Current therapy of KRAS-mutant lung cancer
Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer
Synergistic effects of FGFR1 and PLK1 inhibitors target a metabolic liability in KRAS ‐mutant cancer
Restoration of mutant K-Ras repressed miR-199b inhibits K-Ras mutant non-small cell lung cancer progression
Targeting mutant KRAS in pancreatic cancer: futile or promising?
The cholesterol uptake regulator PCSK9 promotes and is a therapeutic target in APC/KRAS-mutant colorectal cancer
Beyond KRAS: Practical Molecular Targets in Pancreatic Adenocarcinoma
Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
Identification and functional characterization of novel cancer targets in mutant KRAS-driven malignancies
A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
A pan-KRAS degrader for the treatment of KRAS-mutant cancers
Current therapy of KRAS-mutant lung cancer
Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer
Synergistic effects of FGFR1 and PLK1 inhibitors target a metabolic liability in KRAS ‐mutant cancer
Restoration of mutant K-Ras repressed miR-199b inhibits K-Ras mutant non-small cell lung cancer progression
Targeting mutant KRAS in pancreatic cancer: futile or promising?